12,500+
Study Participants
15
Medical Centers
3
Completed Trials
8
Published Papers
98.5%
Accuracy Rate
Phase III Randomized Controlled Trial: DiagnoX vs. Traditional Glucose Monitoring
Study Phase
Phase III
Participants
5,200
Duration
12 Months
Status
Completed

Objective

To evaluate the clinical accuracy, safety, and user satisfaction of the DiagnoX non-invasive glucose monitoring system compared to traditional fingerstick glucometers in adults with Type 1 and Type 2 diabetes.

Methodology

  • Randomized, controlled, multi-center trial across 12 international sites
  • Participants aged 18-75 with confirmed diabetes diagnosis
  • Daily glucose monitoring using both DiagnoX and reference glucometer
  • Quality of life assessments at baseline, 6, and 12 months
  • HbA1c measurements at baseline, 3, 6, 9, and 12 months
  • Adverse event monitoring throughout study period

Key Results

98.5%
Clinical Accuracy vs Reference
0.9%
Mean Absolute Relative Difference
94%
User Satisfaction Score
-0.4%
Mean HbA1c Improvement
0
Serious Adverse Events
78%
Reduced Testing Anxiety

Conclusion

The DiagnoX system demonstrated non-inferiority to traditional glucose monitoring with significantly improved user experience and quality of life metrics. The study met all primary and secondary endpoints with statistical significance (p<0.001).

Published in: New England Journal of Medicine, 2024
DOI: 10.1056/NEJMoa2024001
Impact Factor: 176.1
Download Full Study PDF
Accuracy Validation Study: DiagnoX Optical Glucose Sensing Technology
Study Type
Validation
Participants
3,500
Duration
6 Months
Status
Completed

Objective

To validate the accuracy of DiagnoX optical sensors across diverse populations and glucose ranges, ensuring reliability across different demographics, skin types, and environmental conditions.

Key Results

99.2%
Readings Within Β±15%
97.8%
Readings Within Β±10%
0.87
Correlation Coefficient (r)
Β±12.3
95% Confidence Interval
Published in: Diabetes Technology & Therapeutics, 2024
DOI: 10.1089/dia.2024.0156
Impact Factor: 4.8
Download Full Study PDF
Pediatric Safety and Usability Study of DiagnoX Technology
Study Type
Safety
Participants
850
Age Range
6-17 years
Status
Completed

Objective

To evaluate the safety, usability, and psychological impact of DiagnoX technology in pediatric populations with Type 1 diabetes, focusing on device-related anxiety and treatment compliance.

Key Results

100%
Safety Profile
89%
Reduced Testing Anxiety
92%
Improved Compliance
96%
Parent Satisfaction
Published in: Pediatric Diabetes, 2024
DOI: 10.1111/pedi.13512
Impact Factor: 3.2
Download Full Study PDF

Regulatory Approvals

DiagnoX has received approvals and certifications from leading regulatory bodies worldwide.

πŸ‡ΊπŸ‡Έ

FDA Clearance

510(k) clearance for glucose monitoring device

Approved: March 2024
πŸ‡ͺπŸ‡Ί

CE Marking

European conformity for medical devices

Approved: February 2024
πŸ‡¨πŸ‡¦

Health Canada

Medical device license approved

Approved: April 2024
🌏

TGA Australia

Therapeutic Goods Administration approval

Approved: May 2024

Peer-Reviewed Publications

Our research has been published in leading medical journals with rigorous peer-review processes.

New England Journal of Medicine
Impact Factor: 176.1
Phase III Clinical Trial Results
Diabetes Technology & Therapeutics
Impact Factor: 4.8
Accuracy Validation Study
Pediatric Diabetes
Impact Factor: 3.2
Pediatric Safety Study
Journal of Diabetes Science
Impact Factor: 4.1
Technology Innovation Review

Ongoing & Future Studies

We continue to advance our research with additional studies and real-world evidence collection.

Q2 2025
Long-term Outcomes Study
5-year longitudinal study tracking HbA1c improvements and quality of life metrics in 2,000 participants.
Q3 2025
Gestational Diabetes Trial
Specialized study for pregnant women with gestational diabetes, focusing on maternal and fetal outcomes.
Q4 2025
Pre-diabetes Detection Study
Investigation of DiagnoX capability to identify pre-diabetic conditions and glucose intolerance.
Q1 2026
AI Enhancement Trial
Testing next-generation AI algorithms for personalized glucose prediction and management recommendations.

Research Collaboration

Interested in collaborating on diabetes research? We welcome partnerships with academic institutions, healthcare organizations, and research groups.

Contact Research Team